Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Progress Slow in Development of Useful Biomarkers for Rheumatoid Arthritis Treatment

Thomas R. Collins  |  Issue: September 2016  |  September 8, 2016

“Apparently the fact that a TNF inhibitor interferes with the pro-inflammatory cytokine shuts down some of the components in the body that are measured by the MBDA more than abatacept—even if it doesn’t mean anything clinically or radiologically,” he said.

Dr. Smolen added that patients with high disease activity should be expected to have the lowest rate of no radiographic progression. That has been shown to be the case using the Simplified Disease Activity Index (SDAI), but when using the MBDA, the results partially reverse, Dr. Smolen said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“So is such a biomarker appropriate to inform us about disease activity and correlations?” he asked. “Disease activity assessment appears to be the far better way to go.”

The list of potential biomarkers that have produced similarly dashed hopes is a long one, among them the IL-2 receptor, CD4 cells, IL-12 & IL-23.

The Search Continues

He expects new biomarkers to emerge eventually, but they must be legitimate, he said.

“The search must go on,” he said. “We are running biomarker trials currently. And we will actually find markers. But we will have to find the right ones that really distinguish what we want to distinguish. And we need to ask the right questions.”

Dr. van Vollenhoven said he understands the frustration surrounding the slow progress in the search for biomarkers.

“You can always say, ‘Biomarkers are just around the corner,’ [but] people get tired of that,” he said. “What we were hoping for was that we could find biomarkers that could guide us more in terms of treatment.”

That doesn’t mean the field should give up the search.

The MBDA has its merits, he said. An analysis of data from the SWEFOT trial, which compared conventional with bio­logical treatment in early RA, showed that those with a low or moderate MBDA score at baseline have hardly any radiographic progression after two years, while those with a higher score had what he called “a substantial risk,” with about one in five patients experiencing radiographic progression.

This information could help clinicians discuss patients’ prospects and potentially lead to more intense treatment in some cases, said Dr. van Vollenhoven, who reported working as a consultant for Crescendo Bioscience, the developer of the MBDA test.

Also, he said, the MBDA has been better than traditional measures at predicting which patients are more likely to respond to triple therapy as opposed to anti-TNF therapy. Those data are expected to be published in a forthcoming paper, he said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:BiomarkersEULAREuropean League Against RheumatismprogressResearchRheumatoid arthritisrheumatologistTreatment

Related Articles

    Biomarkers to Guide Diagnosis, Treatment of Rheumatic Diseases

    January 1, 2015

    Examining the usefulness, drawbacks of current biomarkers in rheumatology and progress to develop better ones

    More Evidence Biomarkers Predict RA Relapse with DMARD Taper

    December 28, 2015

    NEW YORK (Reuters Health)—For rheumatoid arthritis (RA) patients in stable remission, a panel of inflammatory markers in blood can help predict the odds of relapse when disease-modifying anti-rheumatic drug (DMARD) therapy is tapered, say researchers from Germany. The multibiomarker disease activity (MBDA) score, when combined with anticitrullinated protein antibody (ACPA) testing, can predict relapse in…

    European Beacon for Rheumatology

    January 1, 2008

    Josef S. Smolen, MD, led the way for outcomes measures and a scientifically based training program

    Rheumatoid Arthritis May Confer Higher Cardiac & Infection Risks

    January 16, 2018

    NEW YORK (Reuters Health)—Patients with rheumatoid arthritis (RA) are at increased risk of serious infections, myocardial infarction (MI) and coronary heart disease (CHD), an analysis of Medicare claims data suggests. “Higher disease activity as measured by a panel of biomarkers was associated with higher rates of hospitalized infections, MI and CHD events. These findings add…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences